...
首页> 外文期刊>Medicine. >Nonanatomical resection is comparable with anatomical resection in solitary hepatocellular carcinoma <5?cm in the right posterior section
【24h】

Nonanatomical resection is comparable with anatomical resection in solitary hepatocellular carcinoma <5?cm in the right posterior section

机译:右后方<5?cm的孤立性肝细胞癌的非解剖切除与解剖切除相当

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Anatomical resection (AR) is superior to nonanatomical resection (NAR) in theory, but the actual clinical benefit of AR for hepatocellular carcinoma (HCC) is controversial due to the substantial heterogeneity of HCC. Here, we retrospectively compared AR and NAR outcomes for solitary hepatocellular carcinoma (HCC) <5 cm in the right posterior section (RPS) and investigated the risk factors for HCC recurrence and liver-related mortality. The study included 99 consecutive patients who underwent curative surgical resection of an HCC in the RPS (S6 and S7) between January 2003 and December 2009. Each patient had a solitary HCC <5 cm and a noncirrhotic liver. The median estimated blood loss during operation and median operative time were significantly worse in the AR group. In addition, the median tumor size and incidence of microvascular invasion were significantly worse in the AR group. The 1-, 3-, and 5-year disease-free survival rates were 74.1%, 66.3%, and 58.2% in the AR group and 84.7%, 64.4%, and 48.2% in the NAR group, respectively ( P = 0.172). The corresponding liver-related overall survival rates were 96.3%, 84.7%, and 77.0% in the AR group and 97.2%, 90.1%, and 88.7% in the NAR group, respectively ( P = 0.335). NAR was not associated with HCC recurrence or liver-related mortality in multivariate analysis. The outcomes of NAR for a solitary HCC <5 cm in the RPS are comparable to those achieved with AR with respect to long-term liver-related overall survival and disease-free survival.
机译:从理论上讲,解剖切除术(AR)优于非解剖切除术(NAR),但由于HCC的实质异质性,AR在肝细胞癌(HCC)上的实际临床益处尚存争议。在这里,我们回顾性比较右后段(RPS)小于5 cm的孤立性肝细胞癌(HCC)的AR和NAR结果,并调查了HCC复发和肝相关死亡率的危险因素。该研究纳入了自2003年1月至2009年12月在RPS(S6和S7)中接受根治性肝癌根治性手术切除的99例连续患者。每例患者的单发HCC <5 cm,肝硬化。在AR组中,术中估计失血量和术中平均手术时间显着恶化。此外,AR组中位肿瘤大小和微血管浸润发生率明显更差。 AR组的1年,3年和5年无病生存率分别为74.1%,66.3%和58.2%,NAR组分别为84.7%,64.4%和48.2%(P = 0.172) )。 AR组和NAR组相应的肝脏相关总生存率分别为96.3%,84.7%和77.0%(P = 0.335)。在多变量分析中,NAR与HCC复发或肝相关死亡率无关。就长期肝相关总体生存和无病生存而言,RPS中单个HCC <5 cm的NAR结果与AR相当。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号